CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company specializing in bladder cancer therapeutics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. Chairman & CEO Arthur Kuan will engage in a fireside chat at the conference in Miami Beach on June 10, 2025, at 11:20 am ET. The presentation will be accessible via live audio webcast through the company's Investor Relations website, with replay available for approximately 90 days post-event. CG Oncology focuses on developing bladder-sparing therapeutic solutions for bladder cancer patients.
CG Oncology (NASDAQ: CGON), un'azienda biofarmaceutica clinica in fase avanzata specializzata in terapie per il cancro alla vescica, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità organizzata da Goldman Sachs. Il Presidente e CEO, Arthur Kuan, parteciperà a una conversazione informale durante la conferenza che si terrà a Miami Beach il 10 giugno 2025 alle 11:20 ET. La presentazione sarà disponibile in diretta audio streaming sul sito web delle Relazioni con gli Investitori della società, con la possibilità di rivederla per circa 90 giorni dopo l'evento. CG Oncology si concentra sullo sviluppo di soluzioni terapeutiche che preservano la vescica per i pazienti affetti da cancro alla vescica.
CG Oncology (NASDAQ: CGON), una compañía biofarmacéutica clínica en etapa avanzada especializada en terapias para el cáncer de vejiga, anunció su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs. El presidente y CEO, Arthur Kuan, participará en una charla informal durante la conferencia en Miami Beach el 10 de junio de 2025 a las 11:20 am ET. La presentación estará disponible en audio en vivo a través del sitio web de Relaciones con Inversionistas de la compañía, con la opción de reproducción disponible por aproximadamente 90 días después del evento. CG Oncology se enfoca en desarrollar soluciones terapéuticas que preservan la vejiga para pacientes con cáncer de vejiga.
CG Oncology(NASDAQ: CGON)는 방광암 치료제에 특화된 후기 임상 단계의 생명공학 제약 회사로, 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회장 겸 CEO인 아서 콴(Arthur Kuan)은 2025년 6월 10일 오전 11시 20분(동부 시간) 마이애미 비치에서 열리는 컨퍼런스에서 파이어사이드 채팅에 참여할 예정입니다. 발표는 회사 투자자 관계 웹사이트를 통해 라이브 오디오 웹캐스트로 제공되며, 행사 후 약 90일간 다시 보기 서비스도 이용할 수 있습니다. CG Oncology는 방광암 환자를 위한 방광 보존 치료 솔루션 개발에 집중하고 있습니다.
CG Oncology (NASDAQ : CGON), une société biopharmaceutique en phase clinique avancée spécialisée dans les traitements du cancer de la vessie, a annoncé sa participation à la 46e conférence mondiale annuelle sur la santé organisée par Goldman Sachs. Le président-directeur général Arthur Kuan participera à une discussion informelle lors de la conférence qui se tiendra à Miami Beach le 10 juin 2025 à 11h20, heure de l’Est. La présentation sera accessible en webcast audio en direct via le site web des relations investisseurs de la société, avec une rediffusion disponible pendant environ 90 jours après l’événement. CG Oncology se concentre sur le développement de solutions thérapeutiques préservant la vessie pour les patients atteints de cancer de la vessie.
CG Oncology (NASDAQ: CGON), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Therapien gegen Blasenkrebs spezialisiert hat, gab seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs bekannt. Vorsitzender und CEO Arthur Kuan wird am 10. Juni 2025 um 11:20 Uhr ET in Miami Beach an einem Fireside-Chat teilnehmen. Die Präsentation wird als Live-Audio-Webcast über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiedergabemöglichkeit für etwa 90 Tage nach der Veranstaltung. CG Oncology konzentriert sich auf die Entwicklung blasenerhaltender therapeutischer Lösungen für Patienten mit Blasenkrebs.
Positive
None.
Negative
None.
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology (508) 654-2277 sarah.connors@cgoncology.com
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
